1

2	Data integration between clinical research and patient care: a
3	framework for context-depending data sharing and in silico
4	predictions
5	
6	
7	
8	Katja Hoffmann ^{1,2*} , Anne Pelz ¹ , Elena Karg ¹ , Andrea Gottschalk ¹ , Thomas Zerjatke ¹ , Silvio
9	Schuster ¹ , Heiko Böhme ² , Ingmar Glauche ¹ , Ingo Roeder ^{1,2}
10	
11	
12	
13	¹ Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus,
14	Technische Universität Dresden, Dresden, Germany
15	² National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
16	
17	
18	*Corresponding author
19	E-mail: katja.hoffmann@tu-dresden.de (KH)
20	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

Usually, it takes quite some time until new insights from basic or clinical research are ultimately transferred into clinical routine. On the other hand, there are still many hurdles to directly provide and use routine data in the context of basic and clinical research. Specifically, no coherent software solution is available that allows a convenient and immediate bidirectional transfer of data between concrete treatment contexts and research settings.

27 Here, we present a generic framework that integrates health data (e.g., clinical, molecular) and 28 computational analytics (e.g., model predictions, statistical evaluations, visualizations) into a 29 clinical software solution which simultaneously supports both patient-specific healthcare 30 decisions and research efforts, while also adhering to the requirements for data protection and 31 data quality. Specifically, we emerge from a recently established generic data management 32 concept, for which we designed and implemented a web-based software framework that 33 integrates data analysis, visualization as well as computer simulation and model prediction 34 with audit trail functionality and a regulation-compliant pseudonymization service. Within the 35 front-end application, we established two tailored views: a *clinical (i.e., treatment context)* 36 perspective focusing on patient-specific data visualization, analysis and outcome prediction, 37 and a research perspective focusing on the exploration of aggregated, but pseudonymized 38 data.

We illustrate the application of our generic framework by two use-cases from the field of haematology/oncology. Our implementation demonstrates the feasibility of an integrated generation and backward propagation of data analysis results and model predictions at an individual patient level into clinical decision-making processes.

43 Author summary

Patient-oriented research is based on comprehensive, quality-assured medical data that is
visualized and analysed to gain knowledge. Based hereon, computer models can be

developed, which e.g., calculate risk scores or predict treatment success. Such approaches 46 47 can be used for risk staging or for selecting the optimal therapy for a specific patient. In recent 48 years, a lot of efforts have been made to develop generic concepts for data processing and for 49 providing the data in the research context. What has been missing so far is a suitable software 50 infrastructure to facilitate the direct backward propagation of scientific results into everyday 51 clinical practice to support the treating clinicians in their decision-making processes. To close 52 this gap, we designed a generic software framework into which, in principle, any computational 53 model or algorithm can be integrated. For demonstration purposes, we developed a web 54 application that integrates two mathematical models from the field of haematology, specifically 55 relating to chronic myeloid leukaemia (CML). Both models calculate the leukaemia recurrence probability of a specific patient, after the intended stopping of the applied therapy. The 56 57 particular prediction is based on patient-specific molecular diagnostic data and can be used 58 for personalized treatment adaptation.

59

60 Introduction

61 Mathematical models and computational algorithms have already proven useful in analysing 62 data, explaining functional relationships of (patho-)physiological mechanisms, and guiding 63 clinical research. Along this line, also computational applications ("apps") are increasingly used 64 to support clinical decision-making (1-3). Prominent examples are risk scores, which provide 65 patient-specific risk estimates by integrating relevant clinical parameters based on mathematical/statistical models (4-6). Furthermore, mathematical models and computer 66 67 simulations for disease progression and treatment response have been developed for several 68 diseases (7-14). As these models are intrinsically based on clinical data, there is an increasing 69 need to provide such data in a structured and secure way. To fully realize the translational 70 potential of both, models and data, it is necessary to establish interfaces that allow the 71 integration of clinical data and corresponding model predictions and provide them in a hospital 72 setting.

73 In our previous work (15) we focused on how patient-specific model predictions can be 74 provided to clinicians within a particular clinical information system (CIS), while we have not 75 considered the full life cycle of clinical and simulation data. However, due to privacy and 76 security aspects, we need to ask how health data from multiple decentralized data sources 77 can be consistently integrated and made available for computer simulations and analytics in 78 general and how analytic and simulation results, e.g., generated to predict an individual 79 patient's future behaviour, can be transferred back to the routine clinical practice. Currently, 80 we are missing technically applicable concepts to integrate the results of data analyses as well 81 as computer simulations and mathematical model predictions in a hospital setting to support 82 decision-making at an individual patient level. Therefore, we here describe a generic concept 83 of integrating data analysis as well as computer simulation results and mathematical model 84 predictions for scientific research and to support decision-making at an individual patient level 85 in a common hospital setting. The described implementation goes beyond our previously 86 published framework (15), specifically in terms of centralised and privacy-compliant

87 management of patient-identifying and medical data and thus for simultaneous use in clinical88 and research settings.

89 Based on the conceptional works on data integration in scientific research (16), we investigated 90 how guality-control, data protection, and ethical requirements can be guaranteed when 91 integrating medical data in the research and clinical context in parallel. We took advantage of 92 the fact that hospitals implement data management concepts for the efficient and legally 93 compliant provision and use of health data with permanent traceability of all data sources with 94 a clear origin, time stamp and authorship. For this purpose, many hospitals are establishing 95 Research Data Management Systems for data pre-processing, storage and provision, 96 sometimes coupled with an Independent Trusted Third Parties (TTP) to centrally regulate 97 personal identifying data and to manage consents, revocations, and pseudonym assignments. Fig 1 shows an example of a generic configuration of data management components from the 98 99 primary data sources to the applications in patient-oriented research.



Fig 1. Example of a generic configuration of data management from the primary data sources to the applications: Patient
 data from various, decentralized, and heterogeneous data sources (Primary Data Sources) are extracted, transformed to

103 harmonized data and loaded into a Data Warehouse (Extract-Transform-Load (ETL): Data Integration). Data transfer points 104 pseudonymize these data and make them available for analysis and specific applications (ETL: Data Distribution). The 105 identifying data, consents, and the pseudonym linkages are managed by an Independent Trusted Third Party or another 106 pseudonymised service/provider. This institution/service also verifies the existence of the required consent before any 107 processing of personal data. Our specific application "Integration of computational models and analytics", which is 108 additionally connected to a Model and Simulation Server, is intended to be used in clinical research (A) and also in clinical 109 practice (B). Both components (outlined in bold red) complement the existing concept of data management in scientific 110 research.

111 Such a typical configuration comprises the selective extraction of heterogeneous patient data, 112 which are stored in various primary data sources, the transformation into a unique target 113 structure, and the loading into a Data Warehouse (cf. Fig 1 "ETL: Data Integration"). This 114 procedure is often denoted as ETL (Extract-Transform-Load) process. The TTP verifies the 115 existence of informed consent for the usage of the required data and provides application-116 specific pseudonyms. This ensures that the pseudonymized medical data do not allow any 117 conclusions about a patient's identity. Eventually, data transfer points (cf. Fig 1 "ETL: Data 118 Distribution") provide the pseudonymized medical data requested for specific applications, 119 which can be used by authorized researchers (e. g. clinical scientist, data analyst, modeler).

120 In contrast to other tools and workflows that have been already developed to provide health 121 data for research (e.g. (17), (18)), the main focus of our approach is on the backward 122 propagation of research findings and data analysis results into the clinical process, illustrated 123 as the "B" arm in Fig 1. Specifically, we investigated how patient-specific predictions based on 124 mathematical models and corresponding computer simulations can be integrated directly into 125 the clinical workflows to support actual clinical decision-making for treatment optimizations.

Our work emerges from a previously established demonstrator software (15) that integrates time course data of residual disease levels for CML patients to provide estimates of their future behaviour. While the focus on CML is a particular example application, the demonstrator itself is flexible to integrate other types of data and underlying models. The application is primarily intended to be used by clinicians as a clinical decision support tool, complementary to existing

131 primary data sources to optimize treatment strategies on a patient-specific level (see Fig 1B).

132 In addition, it can also be used by researchers in the context of scientific projects (see Fig 1A).

- 133 For both use cases, the software application has to fulfil the following criteria:
- Collection, processing, and provision of quality-assured pseudonymized data
 compliant with Data Protection Laws.
- 136 2. Provision of mathematical model predictions and data analyses.
- 137 3. Permanent traceability of all data and computational results with a unique origin, time
 138 stamp, and authorship (i.e., audit trail functionality).
- 139 4. Interactive visualization of medical data and simulation results.
- 140 5. Assignment of individual clinical data and model predictions and/or analyses to
- 141 individual patients in clinical practice (reidentification of pseudonymized data).
- 142 6. User and access control by role-based right management.

143 In the following, we describe our generic software framework (see Fig 2) that ensures all the 144 specified requirements. We illustrate how algorithmic results (e.g., model predictions, analytic 145 results) can be made available to researchers and clinicians directly in their working 146 environment in an accurate, privacy compliant and transparent way. Finally, we present a 147 newly developed web application (cf. the resulting demonstrator) to exemplify the generic 148 software framework for a particular clinical application from the field of haematology/CML.

149

150 **Results**

151 Generic overall design and data flows

152 Based on the generic concept of data management in patient-oriented research (c.f. Fig 1), we 153 developed a software framework that demonstrates how mathematical model predictions, and 154 - in a broader context - any algorithmic/computational procedure can be integrated into clinical 155 practice to support decision-making. Most importantly, our solution strictly complies with 156 standards for data security and pseudonymization and allows audit trail compatible 157 reconstruction of all of the provided analysis results/predictions (i.e., full transparency). To 158 demonstrate the functionality of the software framework, we use the newly developed web 159 application (the resulting demonstrator) as a particular computational application. It is 160 complemented by a model and simulation server, a TTP/pseudonymization server, and an 161 interface to the (Research) Data Management of the hospital. Fig 2 shows the overall design 162 of the framework and illustrates the processes of data provision and access, that are described 163 below.



164

165 Fig 2. Data provision and access of the generic software framework: The Application Database contains exclusively 166 pseudonymized medical data transferred by the data transfer point of the hospital's (Research) Data Management (I) and 167 pseudonymized model predictions of particular computational models calculated by a model and simulation server for 168 modelling and analysis (II) through scheduled tasks. Authorized researchers can retrieve the pseudonymized medical data and 169 model predictions (A). For authorized clinicians, who have to be able to retrieve identifying medical data and model predictions 170 (B) in clinical practice, a reidentification step (III) through the Trusted Third Party has been integrated.

171 Medical data, as input for data analysis and the calculation of model predictions, are provided 172 by a (Research) Data Management (cf. Figs 1 and 2I). This can be any database or data 173 warehouse storing medical data from (various) primary data sources, or also the primary data 174 source itself (cf. Fig 1). Only a suitable data distribution has to be established. Here, the 175 (Research) Data Management transfers exclusively pseudonymized data. No patient-176 identifying data is stored in the Application Database. After the provision of new or updated 177 medical data, new computer simulations are scheduled periodically or event-driven. The 178 results are provided by the Model and Simulation Server and transferred to the Application 179 Database (Fig 2II). In this way, we ensure that the Application Database contains up-to-date 180 simulation results/model predictions based on the most recent pseudonymized medical data.

181 The data access is regulated by a role-based Access and Rights Management to establish 182 different views on the data, e.g., trial-specific roles or department-specific roles. Members of 183 the trial-specific roles can survey a whole spectrum of *pseudonymized* patients from one or 184 more specific clinical trials, potentially involving different sites (see section Research view). 185 Members of the department-specific role (e.g., haematology) have permission to access to the 186 full data set of his/her patients treated in the particular center (see section Clinic view). In the 187 treatment context, the reidentification of pseudonymized medical and simulation data is 188 performed by the TTP (Fig 2III).

189 The resulting demonstrator

190 To demonstrate the generic software framework (cf. Generic overall design and data flows),191 we:

- a) integrated a specific implementation of a model and simulation server (termed MAGPIE (19))
 to manage and execute computational models.
- b) equipped MAGPIE with two mathematical models from the field of haematology (chronic
 myeloid leukemia, CML).
- 196 c) integrated the MOSAIC TTP server for identity, consent and pseudonym management.
- 197 d) added fictitious patients to the identity management module (E-PIX) of the MOSAIC TTP server
- 198 for illustration purposes.
- e) equipped the consent management module (gICS) of the MOSAIC TTP server with informed
- 200 consents for various CML trials (Research view) and the data usage within the haematological
- 201 treatment context (Clinic view).

202 f) generated pseudonyms for each informed consent form using the pseudonym management

203 module (gPAS) of the MOSAIC TTP server.

- 204 g) designed ETL processes for transferring the medical data into the "Application database" that
- are needed for the specific analyses and model predictions.
- h) implemented a role-based user and access management and established roles for the "Clinic
 view" and "Research view" presentation.

The resulting demonstrator is available at <u>https://tu-dresden.de/med/demoserver</u>. A detailed description of the demo server can be found in the following sections and the demo server walkthrough video (S1 File).

211 Access control

212 The demonstrator offers a role-based user and access management and can be adjusted to 213 reflect department-specific roles (e.g., to be accessible for the Haematology Department) and 214 trial-specific roles (to be limited to units involved in a given clinical trial e.g., the "Demonstrator 215 CML Test Trial"). Each role corresponds to a consent implemented in the gICS module of the 216 MOSAIC TTP server. This ensures that only data from patients who gave their written consent 217 to the respective use are finally provided. Depending on the specific role, the user interface 218 menu provides access to patient-specific data within a treatment context (here within the 219 haematological treatment context; see section Clinic view) and/or to pseudonymized data of particular trials (see section Research view). For testing purposes, the resulting demonstrator 220 221 provides guest accounts with the ability to switch between the department specific and the 222 trial-specific roles.

223 Clinic view

Depending on the user role and the corresponding consent of the gICS module of the MOSAIC TTP server, the user can search for identifying patient data via a particular search form. For testing and demonstration purposes, the identity management module of the MOSAIC TTP

server is equipped with a selection of fictitious patients, inspired by but not identical to patient
time courses from the DESTINY trial (NCT01804985, (20)).

229 Once a particular patient had been identified, the gPAS module of the MOSAIC TTP server 230 provides the pseudonym, which is then used to retrieve the medical data and/or the computer 231 simulation results from the Application Database (*re-identification*, see Fig 2III).

232 The "Clinic view" (Fig 3) presents the current medical data (D) and the latest model predictions 233 (E) of the requested patient visualized in a dashboard (C1). The prediction of the recurrence 234 probability after stopping the TKI treatment based on the model "Molecular monitoring during 235 dose reduction" (cf. Computational models and analytics of the resulting demonstrator), is 236 presented in a simplified and optionally in an expert view (E_1 and E_2). The current medical data 237 can be also retrieved and downloaded in form of a table view (Fig 3C2). Finally, the complete 238 history of calculated computer simulation/model prediction can be followed (Figs 3C3 and 4). 239 which allows an audit trail functionality of the computational results. Fig 4 shows a model-240 predicted immune classification based on the "Estimation of immunological leukaemia control" 241 (cf. Computational models and analytics of the resulting demonstrator). For further details 242 about the computational models see section Materials and Methods and the implementation 243 of the demo server at https://tu-dresden.de/med/demoserver.



- 245 Fig 3. Clinic view: After searching for a patient by identifying data (A) and re-identification (B) of the pseudonymized medical
- 246 data and simulation results, the latest medical data (D) and model predictions (E) are visualized as simplified and/or expert
- view (E₁ and E₂) in a dashboard (C1). Furthermore, the current medical data can be displayed and downloaded in table form
- 248 (C2) and all previous predictions can be retrieved, too (audit trail compatibility, (C3) and Fig 4).

251 Research view

252 Controlled by the access management, the resulting demonstrator additionally offers the ability 253 to access pseudonymized data (e.g., from clinical trials) and corresponding, aggregated 254 analyses and simulation/model results (see Fig 5). The demo server yields clinical data sets 255 from several trials from the field of haematology, specifically recent CML trails. Depending on 256 the particular permission status, the user can or cannot access the detailed information of a 257 given clinical trial.

				Home For Clinic 🕶 I	For Research 👻 Logged in as g	uest researcher 🝷
1 to the to be					Trials	
LIST THAIS						
🕂 Add trial						
	Name		Code	ClinicalTrials.gov	EudraCT	Disease
Details	Demonstrator CN	/I Test Trial	Trial CMI			CMI
Details	Demonstrator of		Ind_OWL			ONIE
📃 Details	DESTINY		DESTINY	NCT01804985	2012-004025-24	CML
Details	ENEST1st		ENEST1st	NCT00519090	2009-017775-19	CML
📃 Details	NordCML006		NordCML006	NCT00852566	2008-004106-13	CML
	predi _{CML}	ERACO SYSVMED	European Commission	TECHNISCHE UNIVERSITÄT DRESDEN	About Read The Docs	

258

- Fig 5. Research view List of collected trials: Dependent on permission, the user can retrieve the detailed information of a
 trial, here the guest researcher is only able to retrieve the pseudonymized data and computer analyses of the "Demonstrator
 CML Test Trial".
- The "Detail View" of a specific clinical trial, here the "Demonstrator CML Test Trial" (see Fig 6), provides general information (A), the ability to access and download the pseudonymized medical data (B) and finally, the summary statistics and graphical illustrations for aggregated data (C). Further information about the analyses is provided in the section Example statistics. We wish to emphasized that the specific data analytics serve as an example to demonstrate the general ability of the framework, which can be flexibly extended or adapted to other

- 268 further/different computational analytics and graphical representations according to the needs
- 269 of the physician and/or researcher.

	List trials / 🗐 Details / 🚺 Documents
	Trial details of trial Trial CML
	✓ Edit X Delete
	Trial name: Demonstrator CML Test Trial
	Study code: Trial_CML
	Description: Test trial for prediCt demonstrator
	ClinicalTrials.gov:
	Disease: CML
	Created At: April 11 2021 7:49 p.m.
	Created by: su
	Access to research data
	The trial contains 38 patients.
	• Diagnostic values
	Treatments
	Treatments
	Treatments Data visualization
	Treatments Data visualization Select plot:
	Treatments Data visualization Select plot: Median and interguartile range (with disabled patient specific time courses)
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: A second sec
	• Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Im
(Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Im
•	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and interquartile range (with disabled patient-specific time cources) Median and median of Demonstrator CML Test Trial
•	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) A trial of the second se
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Ima
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Ima
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Ima
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Ima
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Ima
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) Image: Image: Image:
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) C C C C C C C C C C C C C C C C C C C
	 Treatments Data visualization Select plot: Median and interquartile range (with disabled patient-specific time cources) C C ABL/ABL Aggregation from trial Demonstrator CML Test Trial BCR-ABL/ABL Aggregation from trial Demonstrator CML Test Trial(both genders) ⁰ demo_cml_trial_046156 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046166 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046616 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_046666 ⁰ demo_cml_trial_0466666 ⁰ demo_cml_t
	<section-header> Treatments Data visualization Seler plu: Median and interquartile range (with disabled patient-specific time cources) C C-ABL/ABL Aggregation from trial Demonstrator CML Test Trial Mage of the specific time of the specific t</section-header>
	<section-header><section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header></section-header>
	<section-header><section-header><section-header><section-header><section-header><complex-block></complex-block></section-header></section-header></section-header></section-header></section-header>
	<section-header> transmit Data visualization Set provide the state of the</section-header>
	<section-header> treatments Data visualization Set runs Meta nai interquartile range (with disabled patient-specific time cources) C C ABL/ABL Aggregation from trial Demonstrator CML Test Trial O O O O O O O O O O O O O O O O O O O</section-header>
	<section-header> Treatments Data visualization Ster prime Construction of the construction of the construc</section-header>

- 271 Fig 6. Research view Details of a trial: This detailed view consists of general information (A), the ability to retrieve and
- 272 download the current pseudonymized medical data (B) and the visualization of particular medical data and analysis on
- aggregated data (C).

274 Materials and Methods

275 Software environment of the demonstrator

We used the high-level Python Web framework Django (21, 22) to build the frontend web application. Django provides robust security features, a user authentication system, and a fully featured admin interface.

The computer simulations (e.g., model predictions) are generated using an instance of the model and simulation server MAGPIE, which is a software framework, designed for publishing and executing computational models. MAGPIE also offers a full reproducibility of the calculated model predictions (i.e., audit trail functionality). For parameterization and execution of computational models and simulations, the "MAGPIE-API-R" package (19) is used. For a detailed description of the MAGPIE framework and implementation, we refer to Baldow et al. 2017 (23).

The Python framework Plotly/Dash (24) is used to build the interactive visualizations of medical
and simulation results, which are seamlessly embedded in the frontend application.

For identity, consent, and pseudonym management, which are accomplished by the TTP, the MOSAIC Toolbox (25), consisting of E-PIX (Identity Management Module), gICS (Consent Management Module), gPAS (Pseudonym Management Module) and the TTP dispatcher (TTP Workflow Manager Module) developed within the MOSAIC project (26) are used. The reidentification of pseudonymized data is performed by accessing the TTP Dispatcher (18) using the representational state transfer protocol (REST).

The demonstrator is based on an Apache HTTP Server (27) and uses PostgreSQL (28) as a database backend.

Computational models and analytics of the demonstrator 296

297 In the described demonstrator, two mathematical models for predictions on a patient level and 298 a statistical analysis on aggregated data (see below for details) have been implemented for 299 demonstration purposes. The framework itself is not restricted to these two particular models. 300 It allows the deployment of different mathematical models and other algorithms, as long as 301 they are registered in the MAGPIE model database, and feeding generated model predictions 302 into the described workflow. There is no general restriction, neither on the model type nor on 303 the particular implementation/programming language.

304 Example model 1: Molecular monitoring during dose reduction in CML patients

305 The DESTINY trial (#NCT01804985) investigated whether a reduction of tyrosine kinase 306 inhibitor (TKI) dose in CML patients prior to treatment stop can lead to better treatment-free 307 remission rates compared to full dose treatment (29). Based on a reanalysis of these molecular 308 response data, we showed that an increasing BCR-ABL level during the dose reduction phase 309 is indicative for CML recurrences after TKI stop and can be used to risk-stratify patients prior 310 to treatment cessation (5). Given the individual molecular monitoring data during dose 311 reduction, the statistical model implemented within the resulting demonstrator calculates the 312 local slope parameter of the BCR-ABL dynamics and provides a prediction of the patient-313 specific recurrence probability (5).

314 Example model 2: Estimation of immunological leukaemia control

315 We also developed a mathematical model of CML-immune interaction (30), which can be fitted 316 to available time course data of TKI-treated CML patients and after therapy stop. We showed 317 that gualitatively different dynamic treatment response patterns can be characterized in the 318 context of a mathematical model by different stable steady states, describing the individual 319 immune response (31). The different steady states can be interpreted as "immune classes". 320 Specifically, we distinguish between an insufficient immune response (class A) for which a TKI 321 stop does not seem to be appropriate, a sufficient immune response for which one can expect leukaemia control after a TKI stop (class B), and a weak immune response (class C) for which the effectiveness of the immune response cannot be clearly predicted. For a given set of data (as provided within the demonstrator framework), this model can be used to infer patientspecific immune parameters and, therefore, to estimate a probability for his/her assignment to the three immune classes. As the estimated immune parameter are correlated with the patients' recurrence behaviour after treatment cessation, this classification can be used to support the decision-making with respect to TKI stopping.

329 Example statistics: Estimating median time courses

To evaluate particular patient-specific disease dynamics e.g., in comparison with an overall response pattern (e.g., across different studies), one can aggregate data from patient groups or trials. As an example, we calculate and visualize the median and interquartile ranges of the quantitative molecular measurements at different time intervals during treatment (see (32)). This feature is based on pseudonymized data and can be used also outside the treatment context (research view) for all data that are accessible for the particular user (cf. access control).

337

338 **Discussion**

363

339 We have investigated how data analytics, specifically mathematical model predictions and computer simulation results can be integrated into a clinical routine environment to support 340 341 clinical decision-making at an individual patient level and, simultaneously, support scientific 342 research at the level of pseudonymized data. In particular, we examined how quality-assured 343 and harmonized health data from multiple decentralized clinical data sources can be provided 344 to multiple users (in different contexts) for analyses processing (e.g., modelling/simulation) and 345 how analytic results (e.g., mathematical model predictions) can be returned for direct 346 application in clinical practice, ensuring data protection and ethical requirements.

As a result, a generic software framework (c.f. Fig 2) was designed that allows for seamless integration of computational applications into a common concept of Data Management in hospitals. Specifically, we demonstrate the integration and use of a particular application, denoted as "Integration of computational models and analytics". The application can also be regarded as a generic "container" of a variety of different computational subapplication/algorithms.

353 In our particular example, we integrated two mathematical models, which provide different 354 simulation-based predictions for disease and treatment dynamics in individual patients, in the 355 context of TKI-treated CML. Our approach assumes that the data needed for these particular 356 models are available in a (Research) Data Management System. In our specific examples, 357 these are BCR-ABL/ABL time courses as molecular diagnostic data as well as TKI therapy 358 information. We also assume that a pseudonymization service is established to provide and 359 manage the particular patient-identifying data, application-specific consents and pseudonyms. 360 Our work continuous earlier efforts to demonstrated how mathematical model predictions and 361 analytics can be integrated into a specific clinical information system (CIS) (15). In contrast to 362 these previous studies, we are now presenting a stand-alone Clinical Decision Support System

(CDSS) that is intrinsically connected to a (Research) Data Management System (c.f. Fig 1)

364 to retrieve all required medical data. The novel aspect of our current approach lies in the 365 simultaneous provision and usage of health data in both clinical and research contexts 366 (depending on the particular user context). It is not limited to the outlined molecular time course 367 data but can be used for a wide range of health data (e.g., from various CIS, laboratory 368 systems, biobanks) to be integrated for joined analyses, simulations and visualizations. This 369 simultaneous usage is particularly beneficial for clinician scientists in the treatment context 370 since all relevant medical information is available from various primary data sources within a 371 unified and dedicated framework. Our general concept is also flexible in terms of the 372 computational models to be integrated. Future research should therefore investigate what 373 content and requirements are necessary for a user-friendly CDSS within a medical speciality. 374 Furthermore, usability studies can be used to improve the layout and functionalities.

375 Another important advancement of the presented framework is the integration of an 376 independent Trusted Third Party/pseudonymization service as a core element of the research 377 data management infrastructure. Like others (17, 18, 33), we illustrate how health care data 378 can be used for scientific research compliant with data protection. However, to our knowledge, 379 this is the first example to illustrate that this service can also be used to provide patient-specific 380 findings in a backwards manner to directly support clinical decision-making. As of now we are 381 only aware of two pseudonymisation services (25, 34) while only one of them (the MOSAIC 382 Tools) offers the necessary functionalities within our framework (i.e. identity, consent and 383 pseudonym management). Advantages of other pseudonymization services should be 384 addressed in future research projects.

In summary, this paper illustrates and describes how data analytic results, particularly in silico predictions, can be seamlessly integrated into workflows for simultaneous use in research and clinical care routines. We believe that the presented software framework is an ideal basis for further, even commercial developments and the transfer into clinical practice. While we extensively discussed the joined provision of both data and models in a clinical context, we did not elaborate on how the model predictions can actually be compared with future treatment

- 391 outcomes. Such comparison is another step that iteratively contributes to the validation and
- 392 continuous improvement (possibly automated by artificial intelligence) of the models.

393 Acknowledgements

- 394 Not yet applicable.
- 395

References 396

397 Jing X, Himawan L, Law T. Availability and usage of clinical decision support systems 1. 398 (CDSSs) in office-based primary care settings in the USA. BMJ Health Care Inform. 399 2019;26(1).

400 2. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An 401 overview of clinical decision support systems: benefits, risks, and strategies for success. npj 402 Digital Medicine. 2020;3(1):17.

403 3. Harada T, Miyagami T, Kunitomo K, Shimizu T. Clinical Decision Support Systems for 404 Diagnosis in Primary Care: A Scoping Review. International Journal of Environmental 405 Research and Public Health. 2021;18(16):8435.

406 Joseph PV, Wang Y, Fourie NH, Henderson WA. A computational framework for 4. 407 predicting obesity risk based on optimizing and integrating genetic risk score and gene 408 expression profiles. PLOS ONE. 2018;13(5):e0197843.

409 5. Gottschalk A, Glauche I, Cicconi S, Clark RE, Roeder I. Molecular 410 monitoring during dose reduction predicts recurrence after TKI cessation in CML. Blood. 411 2020;135(10):766-9.

412 Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. 6. 413 BOADICEA: a comprehensive breast cancer risk prediction modelincorporating genetic and 414 nongenetic risk factors. Genetics in Medicine. 2019;21(8):1708-18.

415 Cook LM, Araujo A, Pow-Sang JM, Budzevich MM, Basanta D, Lynch CC. Predictive 7. 416 computational modeling to define effective treatment strategies for bone metastatic prostate 417 cancer. Scientific Reports. 2016;6(1):29384.

418 8. Kheifetz Y, Scholz M. Individual prediction of thrombocytopenia at next chemotherapy 419 cycle: Evaluation of dynamic model performances. British Journal of Clinical Pharmacology. 420 2021;87(8):3127-38.

421 Huang S, Hu P, Lakowski TM. Predicting breast cancer drug response using a multiple-9. 422 layer cell line drug response network model. BMC Cancer. 2021;21(1):648.

423 Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. 10. 424 Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with 425 Evolutionary Cancer Modeling. Science Translational Medicine. 2011;3(90):90ra59-90ra59.

426 11. Jain HV, Clinton SK, Bhinder A, Friedman A. Mathematical modeling of prostate cancer 427 progression in response to androgen ablation therapy. Proceedings of the National Academy 428 of Sciences. 2011;108(49):19701-6.

429 12. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, et al. Evolutionary 430 Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase 431 Inhibitors in Non-Small Cell Lung Cancer. Molecular Pharmaceutics. 2011;8(6):2069-79.

432 Noble SL, Sherer E, Hannemann RE, Ramkrishna D, Vik T, Rundell AE. Using adaptive 13. 433 model predictive control to customize maintenance therapy chemotherapeutic dosing for 434 childhood acute lymphoblastic leukemia. Journal of Theoretical Biology. 2010;264(3):990-435 1002.

436 14. Russo G, Palumbo GAP, Salvatore VD, Maimone D, Pappalardo F, editors. 437 Computational models to predict disease course and treatment response in multiple sclerosis. 438 2021 International Conference on Electrical, Computer and Energy Technologies (ICECET); 439 2021 9-10 Dec. 2021.

440 Hoffmann K, Cazemier K, Baldow C, Schuster S, Kheifetz Y, Schirm S, et al. Integration 15. 441 of mathematical model predictions into routine workflows to support clinical decision making in 442 haematology. BMC Medical Informatics and Decision Making. 2020;20(1):28.

443 16. IT-Infrastrukturen in der patientenorientierten Forschung: Aktueller Stand und 444 Handlungsbedarf 2015 / verf. und vorgelegt vom IT-Reviewing Board der TMF-Technologie-445 und Methodenplattform für die Vernetzte Medizinische Forschung e.V. [Hrsg. Johannes 446 Drepper ; Sebastian C. Semler]2016.

447 Bahls T, Pung J, Heinemann S, Hauswaldt J, Demmer I, Blumentritt A, et al. Designing 17. 448 and piloting a generic research architecture and workflows to unlock German primary care 449 data for secondary use. Journal of Translational Medicine. 2020;18(1):394.

450 Bialke M, Penndorf P, Wegner T, Bahls T, Havemann C, Piegsa J, et al. A workflow-18. 451 driven approach to integrate generic software modules in a Trusted Third Party. Journal of 452 Translational Medicine. 2015;13(1):176.

453 19. Baldow C. MAGPIE-API R. 2017.

454 Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-20. 455 escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with 456 stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 457 2 trial. Lancet Haematol. 2017;4(7):e310-e6.

- 458 21. Django. 3.1.6 ed: Django Software Foundation; 2021.
- 459 22. Python Language. 3.6 ed: Python Software Foundation.
- 460 23. Baldow C, Salentin S, Schroeder M, Roeder I, Glauche I. MAGPIE: Simplifying access 461 and execution of computational models in the life sciences. PLOS Computational Biology. 462 2017;13(12):e1005898.
- 463 24. Collaborative data science. Plotly Technologies Inc.; 2015.
- 464 25. Bialke M, Bahls T, Havemann C, Piegsa J, Weitmann K, Wegner T, et al. MOSAIC – A 465 Modular Approach to Data Management in Epidemiological Studies. Methods Inf Med. 466 2015;54(04):364-71.
- 467 26. The MOSAIC-Project 2014 [Available from: http://mosaic-greifswald.de/.
- 468 27. Foundation AS. Apache HTTP Server.
- 469 28. PostgreSQL: a powerful, open source object-relational database system. The 470 PostgreSQL Global Development Group.

471 29. Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-472 escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in 473 patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet 474 Haematol. 2019;6(7):e375-e83.

475 30. Hähnel T, Baldow C, Guilhot J, Guilhot F, Saussele S, Mustjoki S, et al. Model-Based 476 Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML. Cancer Research. 2020;80(11):2394-406. 477

Karg E, Baldow C, Zerjatke T, Clark RE, Roeder I, Fassoni AC, et al. Modelling of 478 31. 479 immune response in chronic myeloid leukemia patients suggests potential for treatment 480 reduction prior to cessation. medRxiv. 2022:2022.06.28.22277004.

481 Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, et al. Quantitative 32. 482 prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib 483 versus dasatinib comparison. Scientific Reports. 2018;8(1):12330.

484 Bruland P, Doods J, Brix T, Dugas M, Storck M. Connecting healthcare and clinical 33. 485 research: Workflow optimizations through seamless integration of EHR, pseudonymization 486 services and EDC systems. International Journal of Medical Informatics. 2018;119:103-8.

487 34. Lablans M, Borg A, Ückert F. A RESTful interface to pseudonymization services in 488 modern web applications. BMC Medical Informatics and Decision Making. 2015;15(1):2.

Supporting information 489

490 S1 File. Walkthrough video of the resulting demonstrator